Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-19 (canceled).

Claim 20. (Original): A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising

administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.

Claim 21. (Original): The method of claim 20, wherein said method is performed *in vitro*.

Claim 22. (Original): The method of claim 20, wherein said method is performed *in vivo*.

Claims 23-25 (Canceled).

Claim 26. (Original): A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising

administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.

Claim 27. (Original): The method of claim 26, wherein said method is performed *in vitro*.

Claim 28. (Original): The method of claim 26, wherein said method is performed *in vivo*.

Claim 29. (Canceled)

Claim 30. (Original): A packaged pharmaceutical composition for treating phospholipase D initiated activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated activity in the subject.

Claim 31 (Canceled).

C3

Claim 32.(Original): A packaged pharmaceutical composition for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject, comprising:

a container holding a therapeutically effective amount of at least one lipoxin compound having the formula



C3 wherein R is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof; and

instructions for using said lipoxin compound for treating PLD initiated superoxide generation or degranulation activity in the subject.